<DOC>
	<DOCNO>NCT01131637</DOCNO>
	<brief_summary>The purpose study evaluate efficacy rhNRG-1 reduce death rate heart failure .</brief_summary>
	<brief_title>Study Survival Recombinant Human Neuregulin-1β Chronic Heart Failure ( CHF ) Patients</brief_title>
	<detailed_description>The mortality chronic heart failure patient remain high , spite recent treatment . RhNRG-1 ( recombinant human neuregulin-1 ) directly work cardiomyocyte restore normal structure function . Both preclinical trial phase II clinical trail confirm rhNRG-1 effectively enhance heart function reverse remodel leave ventricular heart failure animal human . In study , evaluate efficacy rhNRG-1 reduce death rate heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age 18 80 , sex . 2 . Left ventricular ejection fraction ( LVEF ) ≤40 % ( ECHO ) . 3 . NYNA functional class III~Ⅳ . 4 . Clinical symptom steadily late 1 week ( fluid retension , weight gain ) . 5 . Capable signing inform consent form . 1 . Patients acute pulmonary edema acute hemodynamic disorder . 2 . Patients right heart failure cause pulmonary disease . 3 . Patients diagnose pericardial effusion pleural effusion . 4 . Patients myocardial infarction precede 3 month . 5 . Patients constrictive pericarditis , significant valvular pathological change congenital heart disease , severe pulmonary artery hypertension . 6 . Unstable angina pectoris . 7 . Cardiac surgery cerebrovascular accident within recent six month . 8 . Preparing heart transplantation . 9 . Serious ventricular arrhythmia ( multimorphological premature ventricular contraction , frequent paroxysmal ventricular tachycardia ) . 10 . Serious hepatic renal dysfunction cause organic pathological change ( Cr＞3.0mg/dl , AST ALT 10 time normal upper limit ) . 11 . Serum potassium &lt; 3.2 mmol/L &gt; 5.5 mmol/L . 12 . Systolic blood pressure &lt; 90mmHg &gt; 160mmHg . 13 . Pregnant plan pregnant . 14 . Patients participate clinical trial recent three month . 15 . Subject life expectancy le 3 month assess investigator . 16 . Serious nervous system disease ( Alzheimer 's disease , advance Parkinsonism ) . 17 . History malignancy suffer cancer , biopsy proven premalignant condition ( eg DICS cervical atypia ) . 18 . Evidence ( physical examination , CXR , ECHO test ) show active malignancy adenoidal hypertrophy neoplasm effect heart function endocrine system , eg pheochromocytoma hyperthyroidism . 19 . Judging investigator , patient could complete study adhere study requirement ( due management reason others ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>rhNRG-1</keyword>
	<keyword>mortality</keyword>
</DOC>